返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Orthopedics Holds the Second TKA Training Course in Hong Kong

[2017-08-11] 

Hong Kong, China – On July 21, MicroPort® Orthopedics organized a two-day training course regarding total knee arthroplasty ("TKA") surgical technique in Hong Kong. Ten knee replacement experts from Zhejiang, Hebei, Jiangsu, Heilongjiang, Chongqing, Guangdong, Shandong and Hunan provinces attended the course to get a deeper understanding in the design rationale and surgical techniques of the medial-pivot knee.
 
The training course was chaired by Peter KY Chiu, a clinical professor and head of Ortho Recon of the Department of Orthopaedics & Traumatology of the University of Hong Kong, Queen Mary Hospital. As a renowned orthopedic expert, Professor Chiu is a life member of the Hong Kong Orthopaedic Association ("HKOA"). Professor Chiu has been engaged in providing medical education of knee surgical techniques to the Chinese mainland surgeons since 1998. From 2001, approximately 1,700 mainland orthopedic surgeons have come to Hong Kong for the surgical training.
 
This training course focused on how to apply TKA theories to practice. Professor Chun-Hoi Yan, Hon. Secretary of HKOA and Chairman of Adult Joint Recon of HKOA, introduced the biomechanics of a natural knee, following the highlights of the design rationale of the medial-pivot knee. He vividly illustrated the development of the medial pivot knee system, from the initial inspirations of natural knee clinical studies, the pros and cons of the traditional knee prosthesis, to the invention and application of the medial pivot knee. After learning about the medial-pivot knee theoretically, the trainees were divided into four groups for operation demonstrations. The faculty team of Queen Mary Hospital explained to them key surgical skills from approach selection and soft tissue balance skills, to bone cut, alignment management, and sizer management.
 
During the training, Professor Chun-Hoi Yan introduced to trainees the anatomical alignment technique, an emerging surgical technique he has been trying out recently. The technique is gaining higher recognition in the US and Europe markets. It is used to implant the knee prosthesis with anatomical alignment, instead of the mechanical alignment which is the traditional surgical technique. Since the traditional surgical technique changes the alignment of the natural knee, it would exert negative impact on the post-operation experience of patients and the functional stability of the knee prosthesis. Developed based on the relative findings of TKA by Mayo Clinic in the US, the anatomical alignment technique aims to maximize restoring the patient's knee function. During the surgery demonstration, Professor Yan said, EVOLUTION™ CR System is the perfect prosthesis to work with the anatomical alignment technique as it is the total knee prosthesis reserving the most bone and soft tissue and designed in line with biomechanical characters of a natural knee. Meanwhile, EVOLUTION™ CR System achieved clinical outcome exceeding expectations in the first patient enrolled for the follow-up study.
 
This training course provided a thorough comprehension of the design rationale of the medial pivot knee as well as its advantages compared to traditional knee prostheses. Meanwhile, it is expected that the EVOLUTION™ surgical techniques the trainees learnt from the course would lay the foundation for them to carry out EVOLUTION™ surgeries in their local hospitals in the future. MicroPort® Orthopedics will continue to work closely with the Department of Orthopaedics & Traumatology of the University of Hong Kong to launch more TKA training courses, allowing more orthopedic surgeons to understand and use the medial pivot knee so as to benefit more patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Awarded "Pudong Model Enterprise with Well-known Brand in International Trade"
[Next]:MicroPort® Attends 14th Cardiac Imaging & Cardiac Interventional Summit